Normal carcinoembryonic antigen indicates benefit from perioperative chemotherapy to gastric carcinoma patients.

AIM To evaluate pretreatment serum carcinoembryonic antigen (CEA) as a predictor of survival for patients with locally advanced gastric cancer receiving perioperative chemotherapy. METHODS We retrospectively studied a cohort of 228 gastric cancer patients who underwent D2 gastrectomy combined with chemotherapy at the Sun Yat-sen University Cancer Center between January 2005 and December 2009. Among them, 168 patients received 6-12 cycles of oxaliplatin-based adjuvant (post-operative) chemotherapy, while 60 received perioperative chemotherapy (2 cycles of FOLFOX6 or XELOX before surgery and 4-10 cycles after surgery). Serum CEA was measured using an enzyme immunoassay. The follow-up lasted until December 2010. RESULTS In the group that had elevated serum CEA, the difference in survival time between patients receiving perioperative chemotherapy and those receiving adjuvant chemotherapy had no statistical significance (P > 0.05). However, in the group that had normal serum CEA, patients receiving perioperative chemotherapy had a longer survival time. In multivariate analysis, T staging and lymph node metastatic rate were independent prognostic factors for the patients. Perioperative chemotherapy improved the overall survival of patients who had a normal pretreatment CEA level (P = 0.070). CONCLUSION Normal pretreatment serum CEA is a predictor of survival for patients receiving perioperative chemotherapy.

[1]  Jian-Wei Liu,et al.  Chinese Anti鄄 Cancer a Ssociation , 2022 .

[2]  Pui-Jen Tsai,et al.  Chinese Anti鄄 Cancer a Ssociation , 2022 .

[3]  T. Monden,et al.  Paclitaxel-resistant recurrent gastric cancer responsive to docetaxel: a case report. , 2011, Gan to kagaku ryoho. Cancer & chemotherapy.

[4]  S. Lian,et al.  Cost-benefit analysis of screening for esophageal and gastric cardiac cancer , 2011, Chinese journal of cancer.

[5]  P. Schlag,et al.  Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Stuschke,et al.  Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  H. Chung,et al.  Prognostic significance of serum and tissue carcinoembryonic antigen in patients with gastric adenocarcinomas. , 2008, Cancer research and treatment : official journal of Korean Cancer Association.

[8]  Yasuo Ohashi,et al.  Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. , 2007, The New England journal of medicine.

[9]  N. Ogata,et al.  [A case of advanced gastric cancer with obstructive jaundice due to multiple liver metastasis successfully treated with the following combination therapy of CPT-11 and cisplatin after combination therapy of paclitaxel and TS-1]. , 2007, Gan to kagaku ryoho. Cancer & chemotherapy.

[10]  J. Ajani,et al.  Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. V. D. van de Velde,et al.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.

[12]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[13]  J. Ajani,et al.  Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Sakamoto,et al.  The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study , 2003, Gastric Cancer.

[15]  D. Roder,et al.  The epidemiology of gastric cancer , 2002, Gastric Cancer.

[16]  Aller,et al.  Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. , 2002, The New England journal of medicine.

[17]  Scott A. Hundahl,et al.  Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. , 2001, The New England journal of medicine.

[18]  C. Stanners,et al.  Human carcinoembryonic antigen functions as a general inhibitor of anoikis. , 2000, Cancer research.

[19]  H. Ohkura.  Tumor markers in monitoring response to chemotherapy for patients with gastric cancer. , 1999, Japanese journal of clinical oncology.

[20]  N. Takemoto,et al.  Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer. , 1999, Japanese journal of clinical oncology.

[21]  C. Earle,et al.  Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. , 1999, European journal of cancer.

[22]  L. Doyle,et al.  The 95-kilodalton membrane glycoprotein overexpressed in novel multidrug-resistant breast cancer cells is NCA, the nonspecific cross-reacting antigen of carcinoembryonic antigen. , 1997, Cancer research.

[23]  D. Pectasides,et al.  CEA, CA 19-9, and CA-50 in monitoring gastric carcinoma. , 1997, American journal of clinical oncology.

[24]  L. Penn,et al.  Carcinoembryonic Antigen, a Human Tumor Marker, Cooperates with Myc and Bcl-2 in Cellular Transformation , 1997, The Journal of cell biology.

[25]  C. Stanners,et al.  Cell-surface levels of human carcinoembryonic antigen are inversely correlated with colonocyte differentiation in colon carcinogenesis. , 1997, Laboratory investigation; a journal of technical methods and pathology.

[26]  H. Wakimoto,et al.  Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro. , 1996, Cancer research.

[27]  M. Tachibana,et al.  Overexpression of p‐glycoprotein in untreated AFP‐producing gastric carcinoma , 1995, Journal of surgical oncology.

[28]  C. Haglund,et al.  A prognostic value of CA 19-9 but not of CEA in patients with gastric cancer. , 1995, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[29]  C. V. D. van de Velde,et al.  Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  N. Nagasue,et al.  Xenotransplantation of alpha‐fetoprotein‐producing gastric cancers into nude mice. Characteristics and responses to chemotherapy , 1992, Cancer.

[31]  Abraham Fuks,et al.  Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule , 1989, Cell.

[32]  T. Brümmendorf,et al.  Prognostic value of preoperative serum CEA level compared to clinical staging: II. Stomach cancer. , 1982, British Journal of Cancer.

[33]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[34]  Chun-yu Huang,et al.  Prognosis of 980 patients with gastric cancer after surgical resection. , 2010, Chinese journal of cancer.

[35]  H. Juhl,et al.  Inhibition of endogenous carcinoembryonic antigen (CEA) increases the apoptotic rate of colon cancer cells and inhibits metastatic tumor growth , 2004, Clinical & Experimental Metastasis.

[36]  L. Gianni,et al.  Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. , 2002, Tumori.

[37]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.